Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

July 15, 2008; 71 (3) Articles

Cardiorespiratory fitness and brain atrophy in early Alzheimer disease

J. M. Burns, B. B. Cronk, H. S. Anderson, J. E. Donnelly, G. P. Thomas, A. Harsha, W. M. Brooks, R. H. Swerdlow
First published July 14, 2008, DOI: https://doi.org/10.1212/01.wnl.0000317094.86209.cb
J. M. Burns
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. B. Cronk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. S. Anderson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. E. Donnelly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. P. Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Harsha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. M. Brooks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. H. Swerdlow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Cardiorespiratory fitness and brain atrophy in early Alzheimer disease
J. M. Burns, B. B. Cronk, H. S. Anderson, J. E. Donnelly, G. P. Thomas, A. Harsha, W. M. Brooks, R. H. Swerdlow
Neurology Jul 2008, 71 (3) 210-216; DOI: 10.1212/01.wnl.0000317094.86209.cb

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
846

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To examine the correlation of cardiorespiratory fitness with brain atrophy and cognition in early-stage Alzheimer disease (AD).

Background: In normal aging physical fitness appears to mitigate functional and structural age-related brain changes. Whether this is observed in AD is not known.

Methods: Subjects without dementia (n = 64) and subjects with early-stage AD (n = 57) had MRI and standard clinical and psychometric evaluations. Peak oxygen consumption (VO2peak), the standard measure of cardiorespiratory fitness, was assessed during a graded treadmill test. Normalized whole brain volume, a brain atrophy estimate, was determined by MRI. Pearson correlation and linear regression were used to assess fitness in relation to brain volume and cognitive performance.

Results: Cardiorespiratory fitness (VO2peak) was modestly reduced in subjects with AD (34.7 [5.0] mL/kg/min) vs subjects without dementia (38.1 [6.3] mL/kg/min, p = 0.002). In early AD, VO2peak was associated with whole brain volume (beta = 0.35, p = 0.02) and white matter volume (beta = 0.35, p = 0.04) after controlling for age. Controlling for additional covariates of sex, dementia severity, physical activity, and physical frailty did not attenuate the relationships. VO2peak was associated with performance on delayed memory and digit symbol in early AD but not after controlling for age. In participants with no dementia, there was no relationship between fitness and brain atrophy. Fitness in participants with no dementia was associated with better global cognitive performance (r = 0.30, p = 0.02) and performance on Trailmaking A and B, Stroop, and delayed logical memory but not after controlling for age.

Conclusions: Increased cardiorespiratory fitness is associated with reduced brain atrophy in Alzheimer disease (AD). Cardiorespiratory fitness may moderate AD-related brain atrophy or a common underlying AD-related process may impact both brain atrophy and cardiorespiratory fitness.

GLOSSARY: AD = Alzheimer disease; CDR = Clinical Dementia Rating; MMSE = Mini-Mental State Examination; PASE = Physical Activity Scale in the Elderly.

Studies in cognitively normal older adults suggest that maintaining physical fitness may oppose functional and structural changes of the brain that occur with normal aging.1,2 Less is known about the role of exercise and fitness in pathologic brain states, such as Alzheimer disease (AD). A recent meta-analysis of studies utilizing various exercise techniques found evidence that exercise provides some benefits to individuals with dementia3 although studies assessing exercise in AD have produced mixed results.4-8 Animal study data suggest that physical activity can decrease the neuropathologic burden in a mouse model of AD.9 Whether exercise and fitness modify the disease process underlying AD in humans remains unknown.

Studies on physical activity and exercise often rely on self-reported activity measures and are thus limited by a lack of standard and objective definitions of physical activity.10 Maximal treadmill testing to determine peak oxygen consumption (VO2peak) is the standard measure of cardiorespiratory fitness. Cardiorespiratory fitness is closely related to physical activity level11 and is stronger than self-reported physical activity as a predictor of many health outcomes.12 At least one study has demonstrated that healthy older adults with higher cardiorespiratory fitness have lower rates of cognitive decline over 6 years than individuals with lower cardiorespiratory fitness.13 There are little data on cardiorespiratory fitness in AD, particularly in the early stages of the disease. Thus, we performed a cross-sectional study examining cardiorespiratory fitness in relation to brain structure and cognition in individuals in the earliest clinical stages of AD and controls with no dementia. We hypothesized that increased cardiorespiratory fitness would be associated with less brain atrophy and higher cognitive performance in early AD.

METHODS

Sample and recruitment.

Subjects without dementia (Clinical Dementia Rating [CDR] 0, n = 64) and subjects with early-stage AD (CDR 0.5 and 1, n = 57) aged 60 and over were enrolled in the University of Kansas Brain Aging Project. The CDR 0.5 (n = 45) and CDR 1 (n = 12) participants together represent early-stage AD. Study exclusions include neurologic disease other than AD, diabetes mellitus (defined as a clinical diagnosis and use of an antidiabetic agent), history of ischemic heart disease (acute coronary artery event, angina), schizophrenia, clinically significant depressive symptoms, abnormalities in B12, RPR, or thyroid function, use of antipsychotic and investigational medications, and significant visual or auditory impairment, systemic illness, or orthopedic issues that could impair completion of the study.

Clinical assessment.

The clinical assessment included a semi-structured interview with the participant and with a collateral source knowledgeable about the participant. Diagnostic criteria for AD require the gradual onset and progression of impairment in memory and in at least one other cognitive and functional domain.14 The presence or absence of dementia, and its severity if present, was determined using the CDR.15 These methods have a diagnostic accuracy for AD of 93%,16 are sensitive to detecting the earliest stages of AD by focusing on intraindividual change rather than comparison with group norms,17 and are accurate in identifying the subset of individuals meeting criteria for MCI who have early-stage AD.18 Only CDR 0, 0.5, and 1 subjects were enrolled into this study. The CDR sum of boxes was used as a measure of dementia severity.

Medications, past medical history, education, and demographic information were collected from the collateral source by the nurse clinician. A standard physical and neurologic examination was performed to assess abnormalities in visual fields, cranial nerves, motor strength, sensation, reflexes, plantar responses, coordination, praxis, and gait.

Neuropsychological assessment.

A trained psychometrician administered a psychometric battery including standard measures of memory (WMS-R Logical Memory I and II,19 Free and Cued Selective Reminding Task20), language (Boston Naming Test–15 item21), working memory (WMS III Digit Span Forwards and Backwards,19 WAIS Letter-number sequencing22), executive function (Trailmaking A and B,23 Verbal Fluency [animals, fruits and vegetables], and Stroop Color-Word Test24), and visuospatial ability (WAIS Block Design22). The Mini-Mental State Examination (MMSE)25 was administered as a measure of global cognition. Additionally, all cognitive performance scores were converted to z-scores (with higher scores representing better performance) based on the mean and SD of all subjects without dementia and subjects with early-stage AD. The mean of each participant’s performance z-scores was determined to create an index of global cognitive performance.

Cardiorespiratory fitness.

VO2peak, the standard measure of cardiorespiratory fitness, was measured during a symptom-limited graded treadmill test, as previously described.26 Subjects were attached to a 12-lead electrocardiograph to monitor cardiac stability and wore a non-rebreathing facemask. Subjects began walking at a pace of 1.7 miles per hour at 0% grade. Every 2 minutes the speed or grade was increased according to a protocol designed for a geriatric population.27 Blood pressure and the participant’s self-assessment of exertion using the 15-point Borg Rating of Perceived Exertion scale28 were acquired during the last 30 seconds of each 2-minute stage. Heart rates were recorded every 15 seconds. Expired air was measured for oxygen and carbon dioxide at 15-second intervals using a Parvomedics system. Gas calibrations were performed on the metabolic cart before each test according to the specifications of the manufacturer.

VO2peak was considered the highest observed value during the test.29 Participant effort during the treadmill test was assessed with measures of the respiratory exchange ratio (value ≥ 1.0 considered near-maximal effort30) and 17 individuals were excluded for not attaining an RER ≥ 1.0 (6 subjects without dementia vs 11 subjects with early-stage AD, p = 0.17). Subjects excluded for an RER < 1.0 were predominantly women (14 women and three men) and tended to be older than those achieving an RER ≥ 1.0 (77.5 [7.1] vs 73.5 [6.5] years, p = 0.04). There was no difference in global cognition, MMSE, and dementia severity in those excluded vs those achieving an RER ≥ 1.0.

The primary fitness measure was VO2peak normalized by lean mass determined by DEXA scanning (Lunar Prodigy, GE Medical Systems, Madison, WI). This measure was chosen as our primary fitness measure for several reasons. Normalizing VO2peak for lean mass is more physiologic than indexing for body weight29 given that 95% of oxygen consumption during exercise occurs in exercising muscles (i.e., lean mass). Additionally, VO2peak normalized by lean mass minimizes gender differences in VO2peak. For instance, gender differences were not evident in our overall cohort (n = 121) for VO2peak normalized by lean mass (37.1 [6.8] in men vs 36.1 [5.1] mL/kg/min in women, p = 0.37) while robust gender differences are present when normalizing VO2peak for total body weight (24.4 [5.2] in men vs 19.9 [3.6] mL/kg/min in women, p < 0.0001).

Physical activity and frailty assessments.

The participant’s level of habitual physical activity was estimated using the Physical Activity Scale in the Elderly (PASE). The PASE is a reliable and valid measure of physical activity and physical function developed specifically for older individuals.31 The PASE assesses an individual’s level of physical activity within the last 7 days as an estimate of habitual physical activity. We modified the PASE by administering it to the subject’s study partner for both subjects without dementia and subjects with AD. The Physical Performance Test is a short battery of timed physical tasks serving as a composite measure of physical performance and used to assess physical frailty. The modified Physical Performance Test32 includes 1) writing a sentence, 2) simulated eating, 3) lifting a book and placing it on a shelf above shoulder height, 4) putting on and removing a jacket, 5) picking up a penny from the floor, 5) turning 360 degrees and 7) walking 50 feet, 8) chair rises, and 9) a progressive Romberg test.

Neuroimaging.

Structural MRI was obtained using a Siemens 3.0 Tesla Allegra MRI scanner at the Hoglund Brain Imaging Center. High-resolution T1-weighted anatomic images were acquired to provide detailed gross anatomy with high gray-white matter contrast (magnetization-prepared rapid gradient echo; 1 × 1 × 1 mm voxels; repetition time = 2,500, echo time = 4.38, inversion time = 1,100, field of view 256 × 256 with 18% oversample, 1 mm slice thickness, flip angle = 8 degrees). Normalized whole brain volume was computed for each image session using a validated set of imaging tools from FMRIB Software Library (FSL; www.fmrib.ox.ac.uk/fsl). The images were preprocessed and skull-stripped using Brain Extraction Tool. The skull stripped images were then segmented into white matter, gray matter, and CSF using FMRIB’s Automated Segmentation Tool by registering them to a Montreal Neuroimaging Institute avg152 template. Image processing was conducted utilizing the Laboratory of Neuroimaging Pipeline (University of California Los Angeles, www.pipeline.loni.ucla.edu). Normalized volumes for white matter, gray matter, and whole brain (sum of white and gray matter) were calculated by dividing each by the total intracranial volume (the sum of white, gray, and CSF volumes) and expressed as the percent of total intracranial volume. Normalized brain volumes minimize gender differences and produce an estimate of brain atrophy. As expected, normalized whole brain volumes were not related to gender (77.1% [3.3] in women vs 76.9% [3.4] in men, p = 0.76), lending validity to the normalization procedure.

Statistical analyses.

Analyses were conducted using SPSS 15.0. Continuous variables were summarized by means and standard deviations while categorical variables were summarized by frequency and percent. Student t test was used to compare continuous demographic and imaging variables in early AD and no-dementia groups. A χ2 test was used to compare categorical variables. Pearson correlation coefficients were calculated to assess simple relationships between variables. Linear regression was used to assess the relationships between variables while controlling for covariates. A univariate general linear model was used to examine for the presence of group × VO2peak in predicting brain volume. To account for the apparent differential relationship between fitness and brain volume across groups (group × VO2peak interaction, see Results), we conducted all analyses within diagnostic groups (early AD and no-dementia subjects separately) as opposed to the entire cohort combined. To minimize the confounding influence of age-related changes in brain volume we controlled all analyses for age.

RESULTS

Descriptives.

Table 1 summarizes the characteristics of the no-dementia and AD groups. The mean age of the cohort (n = 121) was 73.5 (6.5) years with no difference between no-dementia and early-stage AD groups. Individuals in the early AD group had mild global cognitive dysfunction with a mean MMSE score of 26.2. Whole brain atrophy was apparent in the early AD group, with whole brain differences primarily related to group differences in gray matter volume, consistent with studies suggesting gray matter is more vulnerable to AD than white matter.33,34 Whole brain volume was associated with global cognitive performance (r = 0.53, p < 0.001) and MMSE performance (r = 0.33, p < 0.001).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1 Sample characteristics

Cardiorespiratory fitness.

Modest group differences in cardiorespiratory fitness were observed between AD (34.7 [5.0] mL/kg/min) and no-dementia groups (38.1 [6.3] mL/kg/min, p = 0.002). Group means of peak heart rate and RER were consistent with maximal effort (i.e., 90% of predicted maximum heart rate [220 − age] and RER ≥ 1.1 for both groups). The duration of exercise testing to achieve VO2peak was lower in the early AD group than in participants without dementia.

The role of dementia severity on treadmill testing was examined by assessing the correlation between dementia severity (CDR box score) and measures of effort and VO2peak in the early AD group. Dementia severity was not related to VO2peak (r = −0.09, p = 0.49), RER (r = −0.01, p = 0.94), peak heart rate (r = 0.14, p = 0.30), exercise duration (r = −0.16, p = 0.25), and rating of perceived exertion (r = −0.12, p = 0.37).

Fitness and brain structure.

Simple correlations were first examined between VO2peak, brain atrophy, and cognition (table 2). Given the presence of a group × VO2peak interaction in predicting whole brain volume (p = 0.004), all analyses were performed within diagnostic groups (i.e., no dementia and early AD) rather than the overall group combined. VO2peak was associated with whole brain volume in the early AD group (r = 0.54, p < 0.001; figure 1) but not in controls without dementia (r = 0.18, p = 0.17, figure 2). In early AD, fitness was associated with both white matter volume (r = 0.39, p = 0.003) and gray matter volume (r = 0.36, p = 0.007) with higher fitness levels associated with increased brain volume.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2 Relationship of brain structure and cognition with cardiorespiratory fitness

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1 Relationship between whole brain volume and cardiorespiratory fitness in participants with early Alzheimer disease

Increased fitness levels are associated with increased normalized whole brain volume (less brain atrophy). Filled circles indicate participants with very mild dementia (Clinical Dementia Rating 0.5) and open circles indicated participants with mild dementia (Clinical Dementia Rating 1).

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2 Relationship between whole brain volume and cardiorespiratory fitness in participants with no dementia

Next, these relationships were assessed when controlling for the effect of age (table 1) and other covariates. In early AD, controlling for age did not attenuate the relationship of fitness with whole brain volume (beta = 0.35, p = 0.02) and white matter volume (beta = 0.35, p = 0.04). Additionally, controlling for age and individual covariates of gender, dementia severity (CDR sum of boxes), physical activity level, and a measure of physical frailty (physical performance test) did not alter the relationship of fitness with whole brain volume and white matter volume. An overall model including all covariates did not alter the relationship between fitness and whole brain volume (beta = 0.30, p = 0.03) and partially attenuated the relationship of fitness and white matter volume (beta = 0.27, p = 0.096). After controlling for age, there was no relationship between fitness and gray matter volume in the early AD participants. In participants without dementia, there was no relationship between fitness and whole brain, white matter, and gray matter volumes after controlling for age.

Cognitive performance.

Simple correlations between VO2peak and overall cognitive performance were assessed first. In early AD, VO2peak was not associated with global cognitive performance or performance on the MMSE. On specific cognitive tasks, VO2peak was associated with performance on delayed memory (logical memory II, r = 0.30, p = 0.02) and digit symbol (r = 0.37, p = 0.05) in early AD although these associations were not present when controlling for age. In controls without dementia, VO2peak was associated with global cognitive performance (r = 0.30, p = 0.02) with increasing fitness associated with higher global cognitive performance. On specific cognitive tasks, VO2peak in participants with no dementia was most strongly associated with timed tasks of Trailmaking A (r = −0.32, p = 0.01) and Trailmaking B (r = −0.25, p = 0.005). Additionally, fitness was associated with performance on the Stroop interference task (r = 0.30, p = 0.02), a measure reflecting executive function, and performance on delayed memory (logical memory II; r = 0.26, p = 0.04). These associations, however, were primarily driven by age and were not present when controlling for the effect of age.

DISCUSSION

These results demonstrate a relationship between cardiorespiratory fitness and brain atrophy in the earliest clinical stages of AD. Higher fitness levels in early AD participants were associated with preserved brain volume (less brain atrophy) independent of age and dementia severity. To our knowledge this is the first study to demonstrate a direct relationship between cardiorespiratory fitness and measures of whole brain atrophy in AD. Previous structural neuroimaging studies assessed controls without dementia, rather than AD, using less direct methods (i.e., voxel-based morphometry) to demonstrate regional brain structure (as opposed to whole brain) relationships with fitness. Importantly, the causal nature of these associations cannot be determined due to the cross-sectional design. As a result, at least three explanations for these findings exist: 1) cardiorespiratory fitness moderates AD-related brain atrophy, 2) the AD process itself modifies cardiorespiratory fitness, or 3) a common underlying factor modifies both AD-related brain atrophy and cardiorespiratory fitness.

First, the possibility that enhanced cardiorespiratory fitness may moderate AD-related brain changes is biologically plausible and supported by animal studies. Higher fitness through increased physical activity has been associated with enhanced neuronal survival to brain insults,35,36 increased vascularization,37 and elevations of growth factors in areas important for memory.38,39 Physical activity increases neurogenesis in the hippocampus and enhances learning in mice.40 Additionally, evidence suggests that increased physical activity may modify the AD process. Increased physical activity in an AD mouse model was associated with decreased neuropathologic burden in both cortical and hippocampal regions, suggesting that exercise may mediate the amyloid cascade in favor of reduced production of beta-amyloid.9 Our data are consistent with, but do not establish, cardiorespiratory fitness as a moderating factor in neurodegeneration.

A second explanation of the current results is that the AD process itself may modify an individual’s fitness level resulting in fitness declines co-occurring with AD-related brain atrophy. Behavioral changes associated with the disease include reductions in physical activity,26 which in turn may result in reduced fitness levels. Individuals with AD may also potentially have reduced effort or increased frailty limiting their ability to perform a maximal treadmill test although we found little influence of these factors on the association between fitness and brain atrophy in AD. For instance, controlling for physical activity level (PASE) and physical frailty (physical performance test) did not alter the relationship between fitness and brain atrophy. Additionally, severity of dementia (CDR box score) was not associated with cardiorespiratory fitness or physiologic measures of effort (RER and peak heart rate). All participants met criteria for peak effort (RER ≥ 1.0) while peak heart rate and RER were consistent with maximal effort for both groups. Finally, the 11 subjects with AD excluded for not meeting peak effort criteria did not have more severe dementia or cognitive impairment than those meeting performance criteria, suggesting that reduced effort was not related to dementia severity or cognitive impairment. These observations suggest the relationship between fitness and brain atrophy was not driven by the most severely affected of these subjects with early-stage AD.

Third, it is possible that a common underlying AD-related process may impact both brain atrophy and cardiorespiratory fitness. Additionally, accumulating evidence suggests that AD may not only impact the brain but may have widespread systemic manifestations. For instance, mitochondrial dysfunction is evident in the CNS and periphery in AD43 and abnormalities in metabolic and biochemical processes described in AD brains are reported in peripheral cells such as skin fibroblasts derived from patients with AD.44,45 VO2peak represents the peak rate of metabolic activity (oxygen utilization) in exercising muscle (ml of oxygen consumed per minute per kg of muscle mass) and as such our findings of 1) reduced VO2peak in AD and 2) the correlation of VO2peak with brain atrophy in AD suggests the possibility of metabolic dysfunction co-occurring in brain and muscle. Another possibility is that fitness may modify vascular-related damage (such as white matter lesions and subclinical infarcts) known to influence both brain atrophy41 and cognitive symptoms of AD.42 Further study of the relationship between fitness and vascular-related damage is needed to assess this possibility.

The cross-sectional study design limits the interpretation of the results. Further longitudinal and interventional studies will be necessary to define the role of fitness in modifying the brain aging and AD process. Validated clinical methods were used for diagnosing AD although these methods are imperfect in predicting AD pathology. Additionally, although cardiorespiratory fitness is influenced by physical activity and exercise, this study only assessed the standard measure of cardiorespiratory fitness VO2peak at one point in time and therefore the data should be cautiously interpreted with respect to the role of exercise in early AD.

Footnotes

  • jburns2{at}kumc.edu

    Supported by grants R03AG026374 and R21 AG029615 from the National Institutes of Aging and K23NS058252 from the National Institute on Neurological Disorders and Stroke and by support from the University of Kansas Endowment Association and the Fraternal Order of Eagles. The University of Kansas General Clinical Research Center (M01RR023940) provided essential space, expertise, and nursing support. The Hoglund Brain Imaging Center is supported by grant C76 HF00201 and Dr. Brooks is supported by NS039123 and AG026482. This study utilized the LONI Pipeline environment (http://pipeline.loni.ucla.edu), which was developed by the Laboratory of Neuro Imaging and partially funded by NIH grants P41 RR013642, R01 MH71940, and U54 RR021813. Also supported by Hal Oppenheimer and the Oppenheimer Foundation.

    Disclosure: Dr. Burns has received honoraria for speaking from Pfizer and Novartis and as a consultant from Pfizer. Dr. Swerdlow has received honoraria from Forest, Eisai, Pfizer, and Ortho-McNeil for speaking. There are no disclosures from the other investigators.

    Received December 5, 2007. Accepted in final form March 31, 2008.

REFERENCES

  1. 1.↵
    Colcombe SJ, Erickson KI, Raz N, et al. Aerobic fitness reduces brain tissue loss in aging humans. J Gerontol Ser A Biol Sci Med Sci 2003;58:M176–M180.
    OpenUrl
  2. 2.
    Colcombe SJ, Kramer AF, Erickson KI, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci 2004;101:3316–3321.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004;85:1694–1704.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Broe GA, Creasey H, Jorm AF, et al. Health habits and risk of cognitive impairment and dementia in old age: a prospective study on the effects of exercise, smoking and alcohol consumption. Aust NZ J Public Health 1998;22:621–623.
    OpenUrlCrossRefPubMed
  5. 5.
    Fraser GE, Singh PN, Bennett H. Variables associated with cognitive function in elderly California Seventh-day Adventists. Am J Epidemiol 1996;143:1181–1190.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    Joe V, Richard BL, Mindy JK, Charles BH. Leisure activities and the risk of dementia in the elderly. The N Engl J Med 2003;348:2508.
    OpenUrlCrossRefPubMed
  7. 7.
    Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;45:1161–1168.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    Li G, Shen YC, Chen CH, Zhau YW, Li SR, Lu M. A three-year follow-up study of age-related dementia in an urban area of Beijing. Acta PsychiatrScand 1991;83:99–104.
    OpenUrl
  9. 9.↵
    Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer’s disease. J Neurosci 2005;25:4217–4221.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Blair SN, Church TS. The fitness, obesity, and health equation: is physical activity the common denominator? JAMA 2004;292:1232–1234.
    OpenUrlCrossRefPubMed
  11. 11.↵
    American College of Sports Medicine. Guidelines for exercise testing and prescription Baltimore: Williams & Wilkins; 2000.
  12. 12.↵
    Blair SN, Cheng Y, Holder JS. Is physical activity or physical fitness more important in defining health benefits? Med Sci Sports Exerc 2001;33:S379–S399.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Barnes DE, Yaffe K, Satariano WA, Tager IB. A longitudinal study of cardiorespiratory fitness and cognitive function in healthy older adults. J Am Geriatr Soc 2003;51:459–465.
    OpenUrlCrossRefPubMed
  14. 14.↵
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Morris JC.. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412b–2414.
    OpenUrl
  16. 16.↵
    Berg L, McKeel DW, Jr., Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326–335.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006;67:467–473.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58:397–405.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Wechsler D, Stone CP. Manual: Wechsler Memory Scale. New York: Psychological Corporation; 1973.
  20. 20.↵
    Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology 1988;38:900–903.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Goodglass H, Kaplan E. Boston Naming Test scoring booklet. Philadelphia: Lea & Febiger; 1983.
  22. 22.↵
    Wechsler D.. Manual: Wechsler Adult Intelligence Scale. New York: Psychological Corporation; 1955.
  23. 23.↵
    Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psychological Monographs 1946;60:1–48.
    OpenUrl
  24. 24.↵
    Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643–662.
    OpenUrlCrossRef
  25. 25.↵
    Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 1975;12:189–198.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Burns JM, Mayo MS, Anderson HS, Smith H, Donnelly JE. Cardiorespiratory fitness in early-stage Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:39–46.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Hollenberg M, Ngo LH, Turner D, Tager IB. Treadmill exercise testing in an epidemiologic study of elderly subjects. J Gerontol Biol Sci 1998;53A:259–267.
    OpenUrl
  28. 28.↵
    Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–381.
    OpenUrlPubMed
  29. 29.↵
    Fleg JL, Morrell CH, Bos AG, et al. Accelerated longitudinal decline of aerobic capacity in healthy older adults. Circulation 2005;112:674–682.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation 1997;96:345–354.
    OpenUrlFREE Full Text
  31. 31.↵
    Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol 1999;52:643–651.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Shah KR, Carr D, Roe CM, Miller JP, Coats M, Morris JC. Impaired physical performance and the assessment of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004;18:112–118.
    OpenUrlCrossRefPubMed
  33. 33.↵
    Thompson PM, Hayashi KM, de Zubicaray G, et al. Dynamics of gray matter loss in Alzheimer’s disease. J Neurosci 2003;23:994–1005.
    OpenUrlAbstract/FREE Full Text
  34. 34.
    Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology 2005;564:1032–1039.
    OpenUrl
  35. 35.↵
    Stummer W, Weber K, Tranmer B, Baethmann A, Kempski O. Reduced mortality and brain damage after locomotor activity in gerbil forebrain ischemia. Stroke 1994;25:1862–1869.
    OpenUrlAbstract/FREE Full Text
  36. 36.
    Carro E, Trejo JL, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci 2001;21:5678–5684.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Black JE, Isaacs KR, Anderson BJ, Alcantara AA, Greenough WT. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. Proc Natl Acad Sci USA 1990;87:5568–5572.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Neeper SA, Gomezpinilla F, Choi J, Cotman C. Exercise and brain neurotrophins. Nature 1995;373:109.
    OpenUrlCrossRefPubMed
  39. 39.
    Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002;25:295–301.
    OpenUrlCrossRefPubMed
  40. 40.↵
    van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 2005;25:8680–8685.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    Hugenschmidt CE, Peiffer AM, Kraft RA, et al. Relating imaging indices of white matter integrity and volume in healthy older adults. Cereb Cortex 2008;18:433–442.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    Burns JM, Church JA, Johnson DK, et al. white matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch Neurol 2005;62:1870–1876.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Swerdlow RHK. Mitochondria in Alzheimer’s disease Int Rev Neurobiol 2002;53:341–385.
    OpenUrlPubMed
  44. 44.↵
    Etcheberrigaray R, Ibarreta D. [Ionic channels and second messenger alterations in Alzheimer’s disease. Relevance of studies in nonneuronal cells.] Rev Neurol 2001;33:740–749.
    OpenUrlPubMed
  45. 45.
    Bruel A, Cherqui G, Columelli S, et al. Reduced protein kinase C activity in sporadic Alzheimer’s disease fibroblasts. Neurosci Lett 1991;133:89–92.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • Alzheimer's disease
  • MRI
  • Volumetric MRI

Alert Me

  • Alert me when eletters are published
Neurology: 96 (8)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise